Oestrogens exert their actions via specific nuclear protein receptors that are members of the steroid/ thyroid receptor superfamily of transcription factors. Recently, a second oestrogen receptor (ER ) has been cloned, and using reverse transcription
INTRODUCTION
Steroid action is mediated by specific intracellular receptors which bind ligand and transclocate to the nucleus to activate gene transcription (Brinkmann 1994) . The recently discovered beta isoform of oestrogen receptor (ER ) that shows ligand specificity for oestrogens is expressed in a number of rat tissues . However, some of the data originally reported for the tissue distribution of ER in rat and mouse using reverse transcription (RT)-PCR and RNase protection assay techniques (Couse et al. 1997a , Mitchner et al. 1997 differ from the data obtained using ER immunohistochemistry (Saunders et al. , 1998 .
Most studies on the expression of ER in the human have used RNA techniques such as RT-PCR, RNase protection assays and in situ hybridisation (Byers et al. 1997 . The first two methods are powerful tools to describe the presence of a particular gene in a tissue; however, they do not give a good indication of the type of cell that expresses the gene of interest. In situ hybridisation overcomes the problem of cellular localisation, but the technique is often difficult and the physiological relevance of the data is often difficult to interpret, because the expression of a particular mRNA does not always correspond with the expression of the functional protein. Immunohistochemistry overcomes the problem of identifying the precise cellular localisation of a particular mRNA does not always correspond with the expression of the functional protein. Immunohistochemistry overcomes the problem of identifying the precise cellular localisation of a, presumably, functional protein product. Although comprehensive and detailed immunohistochemical localisation of ER in the rat has recently been reported (Sar & Welsch 1999) , there is no comprehensive report on the localisation of ER protein in the human, only studies of selected tissues (Van Pelt et al. 1999) .
The present study was undertaken to identify those tissues in the human that express ER protein, to compare these results with those of the rat and to identify human tissues that might respond to oestrogen via ER rather than ER . Additionally, the pattern of ER expression was compared with the pattern of ER expression.
ER and ER were successfully immunolocalised to several tissues in both male and female samples. The highest degree of ER nuclear staining was found in the ovary, breast and uterus, but differed from the pattern of ER staining. Male reproductive tissue showed expression of ER in most tissues, with highest expression in the prostate, an ER -negative tissue. In other organs and structures, ER and ER were observed but not always in the same cell type. Some human cells produce ER but do not produce ER , suggesting that oestrogen action in some human tissues may be mediated via the activation of ER rather than ER .
MATERIALS AND METHODS

Antibodies
The monoclonal mouse anti-bovine ER (05-394) antibodies directed against SDS-solubilised calf uterus ER , and polyclonal rabbit anti-rat ER (06-629) antibodies developed against the Nterminal region of the human ER sequence were purchased from Upstate Biotechnology, Lake Placid, NY, USA. An additional polyclonal rabbit anti-rat ER (310) antiserum developed against the C-terminal region of the human ER sequence was purchased from Affinity Bioreagents Inc., Golden, CO, USA. The avidin-biotin blocking solution kit was from Vector Laboratories, Peterborough, Cambs, UK.
Immunohistochemistry
Normal human tissue samples obtained from adult human cadavers post mortem or from patients at the time of surgery for various pathological conditions were fixed in formol saline at the optimal rate of 1 cm 3 /15·6 h (Polak & Van Noorden 1997) or for a fixed period of 24 h before processing into paraffin wax. Additional archival specimens were obtained from the Pathology Department at Leicester Royal Infirmary, Leicester, UK. Sections (4 µm) were mounted onto silane-coated slides and allowed to dry at 37 C for 48 h. Samples were de-waxed, rehydrated and endogenous peroxidase activity quenched using hydrogen peroxide (6% v/v). After washing in double-distilled water for 5 min, sections were subjected to microwave antigen retrieval in 0·01 M citrate buffer, pH 6·0, for 30 min at 750 Watts power. Sections were allowed to cool undisturbed to approximately 37 C over the next 30 min, washed (5 min each) in de-ionised H 2 O and then in PBS-Tween 20 (0·05% v/v), and were blocked for 1 h with PBS containing 1% BSA. Sections were further blocked with normal swine serum or normal rabbit serum for 1 h for the detection of ER or ER respectively. The sections were further blocked with avidin-biotin blocking solution according to the manufacturer's instructions. Excess liquid was removed from around the section and the slide was incubated with anti-ER or anti-ER (1:50) in a humidified chamber for 18 h at 4 C. After washing in PBS-Tween 20, sections were incubated with biotinylated swine anti-rabbit (ER ) or biotinylated rabbit anti-mouse (ER ) immunoglobulins (Dako, Glostrup, Denmark) diluted 1:400 in PBS for 30 min. After a further wash in PBS-Tween 20 (30 min), the sections were incubated with horseradish-peroxidase avidinbiotin complex (Vector) for 30 min. After an additional wash in PBS-Tween 20 (30 min), bound antibodies were visualised with 0·05% diaminobenzadine (DAB) in 0·05 M Tris-HCl, pH 7·4, and 0·01% hydrogen peroxide, according to the supplier's instructions (Vector Elite kit). Sections were then washed in running tap water for 5 min, submerged in CuSO 4 /NaCl solution (5 min), rewashed in tap water, dehydrated through graded alcohol, cleared with xylene and permanently mounted using XAM mounting medium (BDH, Poole, Dorset, UK). Specificity of immunostaining was confirmed using either pre-immune rabbit serum or purified mouse immunoglobulin G (IgG), as appropriate. Additionally, several control sections were produced by omission of the primary antibody or by incubation of anti-ER with 500 µM immunising peptide (a gift from S Boyd, Upstate Biotechnology or Affinity Bioreagents Inc.) or control protein (BSA) for 20 min at 37 C prior to immunodetection. Images were captured on Fujichrome tungsten slide film using a Zeiss Axioplan microscope. All images are representative of at least two samples, analysed at least twice.
RESULTS AND DISCUSSION
Using polyclonal antisera raised against specific peptides localised at the N-terminal and C-terminal ends of the human ER sequence, ER was immunolocalised to cell nuclei in multiple tissues ( Table 1 ). The pattern of expression for both antibodies was identical in all tissues studied (see examples in Figs 1-3) . The C-terminal antibody has recently been used to show the immunolocalisation of ER in the female rat brain (Li et al. 1997 , Alves et al. 1998 . The monoclonal ER showed specific staining in tissues previously reported to be positive for ER , such as breast, vagina and ovary (Fig. 1) . ER was weakly expressed in ovarian granulosa and luteal cells (Fig. 1A) and differed in its level of expression compared with ER ( Fig. 1B to K) .
The highest level of ER expression was found in the nuclei of granulosa cells of small, medium and large ovarian follicles (Fig. 1B to G) . ER immuroeactivity to ovarian granulosa cells could be inhibited by pre-incubation of the C-terminal antibody with 500 µM immunising peptide but not with BSA ( Fig. 1C and B respectively) . Additionally, staining results with the N-terminal (Fig. 1D ) and C-terminal (Fig. 1E) were comparable. Similarly, the ER immunoreactivity to ovarian granulosa cells could be inhibited by pre-incubation of the N-terminal antibody with excess immunising peptide but not with excess C-terminal immunising peptide ( Fig. 1F and G respectively). ER was detectable in the stroma of the ovary, but not in the corpus luteum (Fig. 1H) , whereas ER was found in the ovarian stroma and corpus luteum using both the N-terminal and C-terminal antibodies ( Fig. 1I and J). Additional staining was also observed in primordial follicles (Fig. 1K ).
These data are consistent with the results of in situ hybridisations (Byers et al. 1997 and with ER expression in rat ) and bovine ovaries. The nuclei of human corpora lutea and corpora albicans showed significant levels of ER expression but, contrary to studies in the rat, some staining of cytoplasmic ER was found in both the human corpora lutea and corpora albicans (data not shown). ER was also found in the nuclei of granulosa cells and ovarian stroma but not in corpora lutea/albicans, and ER levels were lower, which is consistent with the studies of Byers et al. (1997) who found significantly lower expression of ER mRNA compared with ER mRNA. Specific nuclear staining was almost completely abolished by incubation of the primary antibody with the peptide used for immunisation ( Fig. 1C and F ), but not with an unrelated peptide (BSA) (Fig. 1B and G) . Other tissues of the female reproductive tract showed specific ER expression -Fallopian tube, uterus, cervix and vagina -with most of the expression confined to nuclear staining of epithelial cells ( Fig. 1L to S). Some diffusion of staining to the cytoplasm of several epithelial cell types was observed (Fig. 1L , Q and S) and in the squamous epithelial cell layer of the vaginal wall (Fig. 1P ). Endothelial cells in capillaries (Fig. 1N ) and major blood vessels of all tissues studied showed only nuclear ER staining. These data suggest that cells in some tissues express only a nuclear ER receptor and other cells produce both nuclear and cytoplasmic forms of the beta-receptor. Because staining with both N-terminal and C-terminal antibodies was identical, the truncated ER isoforms recently reported (Moore et al. 1998 , Ogawa et al. 1998a ) are unlikely to be expressed, because a higher staining pattern with the N-terminal antibody would be predicted. There is currently little evidence that the truncated ER isoforms have any physiological relevance, except using in vitro reporter assays (Ogawa et al. 1998b) , where data indicate that the truncated isoforms may inhibit activation of the full-length ER isoform. We observed a decrease in ER staining in the transition of resting to proliferative human breast that may support this notion.
Increased ER immunoreactivity was noted in the glands of normal resting breast when compared with the glands of proliferating breast ( Fig. 1Q and R). Some ER staining was found in the cytoplasm of the resting breast epithelium, but both cytoplasmic and nuclear ER epithelial staining was reduced in the proliferating breast. ER was also present in the resting breast stroma, but almost absent in the proliferating breast. Recent studies have highlighted the fact that ER may be very important in breast tumorigenesis (Hu et al. 1998 , Leygue et al. 1998 , Vladusic et al. 1998 , with an apparent increase in ER transcription during the hyperplastic phase. However, the apparent increase in ER mRNA levels could be attributed to an increase in cell number and not to a direct increase in transcriptional rates for ER . Indeed, our data suggest that the opposite is true. During activation of the normal breast, the ER protein concentration decreases, but there is an apparent increase in the number of ER -positive cells. This observation may explain the apparent ER mRNA increase reported in transformed MCF-7 cells (Hu et al. 1998) . The protein concentration per cell is presumably dependent upon the stability of ER mRNA, which is currently unknown in breast tissue. Alternatively, during the proliferative process, ER transcription increases, but ER translation decreases. 
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We also observed ER protein staining in adipose tissues, including that of the breast, confirming that breast adipose ER mRNA (Crandell et al. 1998 ) is probably translated into functional protein. What physiological role, if any, ER has in the breast remains unknown, but, predictably, it is an area for further investigation.
The uterus showed nuclear expression of both ER and ER within the stroma of the endometrium, luminal epithelial cells and the entire myometrium. Expression of ER was absent from nuclei of most glandular epithelial cells (Fig. 1M) with some diffuse cytoplasmic staining detectable in some glandular epithelial cells at the neck of the gland (Fig. 1M) , suggesting the presence of ER in these cells. The nuclei of luminal epithelial cells were rich in ER , but at the interface between luminal epithelial cells and glandular epithelial cells expression appears to diminish and lessen deeper into the gland (Fig. 1M) . In contrast to the glandular epithelial cells, ER was found in the nuclei of all stromal cells (Fig. 1M) . ER , by contrast, was found in the nuclei of luminal epithelial cells, glandular epithelial cells and stromal cells (data not shown), which is consistent with the work of others (Lessey et al. 1988 , Amso et al. 1994 , Tibbetts et al. 1998 , Matsuzaki et al. 1999 .
The pattern of ER expression in the human endometrium differs from that reported in the rat, where nuclear ER was found in many epithelial cell types but no cytoplasmic stain was observed . The significance of this differential ER expression between the rat and human uterus is unclear but may have implications on the use of rodents in the study of the growth-stimulatory response of the uterus to oestrogens. The lack of ER expression in the glandular epithelial cells of the human uterus may reflect the specimens used. The samples were obtained from women in the late secretory phase of the menstrual cycle. It is possible that the ER status of the human glandular epithelial cells may change during the menstrual cycle, as a recent report suggests, with the levels of ER changing from 'very strong' for proliferative endometria to 'very weak' for secretory endometria (Matsuzaki et al. 1999) . Additionally, these authors report the presence of ER mRNA in stromal cells but at a lower level compared with glandular epithelial cells, and that stromal ER mRNA levels remain constant throughout the menstrual cycle. We have examined more than 30 endometrial specimens and have not been able to detect ER in the glandular epithelial cells of proliferative or secretory endometria. This suggests that although these cells may contain ER mRNA, the protein is not expressed and that ER may have no physiological role in the endometrial glandular epithelial cells. Alternatively, it is also possible that ER expression in glandular epithelial cells is regulated by interactions with other members of the steroid receptor superfamily in a temporal manner, just as progesterone receptor is regulated by ER and retinoic acid receptor (Savouret et al. 1994) .
The male urogenital system showed immunoreactive staining for both ER ( Fig. 2A and Table 1) and ER (Fig. 2B to K and Table 1 ). Staining was confined to nuclei of mostly luminal epithelial cells of many tissues except the epididymis (Fig. 2L) where extensive cytoplasmic staining was visible. As expected, high levels of ER were found in the prostate with both the N-terminal antibody (Fig. 2B ) and the C-terminal antibody (Fig. 2C and  D) . ER was also localised to collecting duct tubules of the renal medulla ( Fig. 2F and G) , but, significantly, not to renal glomeruli or renal cortical tubules (Fig. 2E) . Loops of Henlé and capillaries were also negative for ER and, interestingly, ER was consistently localised to the basal surface of epithelial cells lining the collecting ducts (Fig. 2G) . The bladder (Fig. 2H) showed specific ER staining in the nuclei of epithelial and smooth muscle cells, and the epididymis showed staining in basal cells, principal cells, smooth muscle cells and cells that constitute the connective tissue layer (Fig. 2I) . Epithelial cells and smooth muscle cells of the ductus deferens also showed specific ER staining (data not shown). A high level of nuclear ER staining was observed with both the N-terminal (Fig. 2J ) and the C-terminal (Fig. 2K) antibodies. Spermatocytes, Sertoli cells, interstitial cells and spermatogonia all showed specific ER immunoreactivity.
The staining pattern for ER in the human male urogenital tract was associated with many cell types involved in semen development and secretion. In particular, the staining pattern in the testis and prostate was similar to that seen in the adult male rat (Saunders et al. , 1998 . However, the finding of specific ER staining to the basal surface of kidney collecting duct tubules, but not to the cytoplasm or the nucleus (Fig. 2F and G) is difficult to explain. Historically, the human kidney has been thought to be unreactive to oestrogen stimulation, although renal carcinogenesis is inducible with oestrogens in the rodent (Bhat et al. 1993) . Therefore, the presence of immunoreactive ER and ER in the human kidney is surprising. However, recent data (Hardy et al. 1999) suggest that oestradiol can interact on the basal surface of proximal tubule cells to increase kidney androgenregulated protein (KAP), suggesting the possibility of an ER -dependent effect in the human kidney. ER was found in both renal medullae and cortexes, but isolated to the nuclei of cells constituting the Loop of Henlé and renal corpuscle (data not shown). ER was absent from the collecting ducts, suggesting that oestrogen-dependent effects in these cells occurs only through ER -dependent mechanisms. Additionally, the intensity of ER staining in the male samples was more intense than that of ER (data not shown), suggesting that a high estrogen environment may affect ER expression in some tissues, as has been suggested by others (Chu & Fuller 1997) . ER expression was not confined to the female and male reproductive tracts. The oesophagus, lung, small intestine, heart, many areas of the brain, thyroid, stomach, intestine, rectum, smooth muscle cells and endothelial cells of blood vessels were all positive for ER (Table 1 and Fig. 3 ). Both ER isoforms were found in the nuclei of cells of the tissues described (see Table 1 ), with the exception of hepatocytes and the hippocampus where only ER was observed. Although ER has previously been demonstrated in the rat hippocampus (Li et al. 1997) , we were unable to detect significant ER staining in the human hippocampus (Fig. 3J) . ER was detectable in human hippocampus (Fig. 3I) but ER was not considered to be present, even though some very weak staining could be seen (Fig. 3J) . These data suggest that ER is not expressed in the human hippocampus, or that the antigen retrieval method used in the present study was insufficient to unmask the formalin-induced cross-links. In the original use of the C-terminal antibody in the rat (Li et al. 1997) , the hippocampus was perfused with 2% acrolein and used as cryosections. Therefore, it follows that some of the cells and tissues reported herein to be negative for ER may be proved to be immunopositive under different fixation/unmasking conditions.
Although the distribution of the ER isoform appears to be closely related to the expression of ER in most tissues (Table 1) , ER expression does not appear to be linked to ER expression. Some ER -positive cells lack ER and vice versa (see Table 1 ), raising the possibility that there are distinct ER -and ER -dependent transcriptional pathways. For example, the prostate lacks ER but contains ER , leading to the conclusion that the clinical treatment of the prostate for prostatic cancer (Carlstrom et al. 1997) can be mediated only through an ER -dependent pathway.
The data presented are qualitatively similar to those found for the rat , with the minor exceptions stated above. Additionally, the pattern of ER protein expression in most human tissues is similar to the pattern of ER transcript expression. For example, ER protein was detected in tissues shown to have ER transcript such as lung and adrenal (Kuiper et al.1997) , heart (Grohe et al. 1998) , rat forebrain (Shughrue et al. 1997 , Osterlund et al. 1998 and aorta. In the aorta, ER may have an important regulatory role since it has recently been shown to increase in rats subjected to experimental injury (Lindner et al. 1998) .
To our knowledge, this is the first report to indicate that ER protein is expressed in the adult human thyroid, gastrointestinal tract and renal collecting duct tubules, although ER transcripts were found in the kidney of the mid-gestational human fetus (Brandenberger et al. 1997) .
The availability of specific antisera to ER will aid the investigation of this novel protein in the human. These antisera complement the RT-PCR and RNase-protection assays performed elsewhere, but, as detailed in the Introduction, RNA techniques only measure relative levels of RNA expression in an entire tissue homogenate, whereas this study and that of Saunders et al. (1997) establish the precise cellular localisation of the protein. A limited number of studies using in situ hybridisation has been used to identify cellular expression of ER in the ovary (Byers et al. 1997) , testis (Couse et al. 1997b ) and brain (Shugrue et al. 1996 , Register et al. 1998 , Shugrue 1998 . However, the data reported previously are contradicted by some of the data presented here and by the rat ER immunolocalisation study . For example, in Byer's in situ hybridisation study (Byers et al. 1997) , ER mRNA was undetectable in the corpus luteum of the normal rat ovary, yet ER protein is readily detectable in the rat ovary . We also observed ER protein in the human corpus luteum (see Fig. 1F and G) and in the nuclei of ovarian surface epithelia, confirming previous findings , Hillier et al. 1998 .
This study extends all the preceding body of work by examining the immunological localisation of ER in human tissues not studied by previous authors. However, there are other discrepancies between our study and that of others (Couse et al. 1997a . Although we have shown ER to be expressed in the uterus, we could not detect ER in the endometrial glandular epithelial cells. This disagrees with the original data presented by Couse et al. (1997a) , who reported the absence of ER RNA in the uterus, suggesting that ER was not expressed in the uterus. Later, the same group reported ER to be weakly expressed (Couse et al. 1997b) . However, there is no indication in their study which cells were weakly expressing ER .
The cellular distribution of ER in the human uterus also shows minor discrepancies when compared with its distribution in the rat uterus. The rat shows ER expression in all cell types, whereas ER expression was undetectable in human endometrial glandular epithelial cells. However, the rat uteri were removed on the day of pro-oestrus, whereas our samples were removed at 7-10 days post-ovulation, suggesting that ER may be differentially expressed throughout the menstrual cycle. However, although in situ hybridization studies suggest that ER is probably down-regulated towards the end of the menstrual cycle (Matsuzaki et al. 1999) , because the staining was weak, the authors may be over-interpreting their data. This is another area that needs clarification.
In the rat immunolocalisation study, ER was undetectable in rat ovarian granulosa cells. We observed specific staining for ER in human ovarian granulosa cells (Table 1) , as did others (Revelli et al. 1996) . The reason for the discrepancy between the immunolocalisation of rat and human ER in human granulosa cells is unknown, but may relate to the methods used to prepare tissues prior to immunohistochemistry. We have found that steroid receptor proteins are susceptible to loss if tissue is not fixed in formol saline at the optimal rate of 1 cm 3 /15·6 h (authors' unpublished observations), as described by others (Taylor et al. 1994 ). Additionally, it is possible that the ER antibodies used in our study are better suited for immunohistochemical techniques. Certainly, there are anti-rat ER antibodies that function well in immunoblotting procedures but not in immunohistochemical methods, and vice versa (Fisher et al. 1997) . The anti-bovine ER antibody (05-394) that we used in this study is useful in both immunohistochemistry and immunoblotting methods. Cells of oestrogenresponsive tissues (e.g. the female reproductive tract, breast, etc.) showed intense nuclear ER staining, as expected (Table 1) , indicating the specificity and usefulness of the ER antibody used for the present study.
Future work will assess the expression of these nuclear receptors in the uterus during the menstrual cycle and look for potential mechanisms that control their expression.
In conclusion, the recent discovery of ER means that the potential sites of oestrogen action may have to be re-evaluated. This paper points at potential starting points for investigation in the human, and at potential discrepancies between rodents and man. This latter point may become more important in the interpretation of many experiments using exogenous and synthetic oestrogen.
